Anki Malmborg Hager

Director/Board Member at SENZAGEN AB

61 year

Health Technology

Consumer Services

Finance

Profile

Cecilia Ann-Christin Malmborg Hager is currently Chief Executive Officer at Lead Biologics International AB. Director at PainDrainer AB since 2019.
Independent Director at SenzaGen AB since 2019.
Director at Diaprost AB, Hager Consulting AB, and Colzyx AB. Formerly Chief Executive Officer at WC Likvid AB, Cantargia AB (2013–2014), Sista versen 26366 AB, Executive Foundation Lund, and Xlmmune AB. Investment Director at Lund University Bioscience AB (2009–2011).
Independent Director at Immunovia AB and NanoEcho AB (2022–2026).
Director and Business Manager at ProNoxis AB. Director at Bulb Intelligence AB and Avena Partners AB. Vice President-Business Development at Alligator Bioscience AB. Educated at the University of Lund with graduate and doctorate degrees.

Anki Malmborg Hager active positions

Companies	Position	Start
SENZAGEN AB	Director/Board Member	2019-06-16
Hager Consulting AB	Director/Board Member	-
PainDrainer AB PainDrainer AB Medical SpecialtiesHealth Technology Develops digital pain management tools	Director/Board Member	2019-08-31
Diaprost AB Diaprost AB Miscellaneous Commercial ServicesCommercial Services Provides research services	Director/Board Member	-
Colzyx AB Colzyx AB Medical SpecialtiesHealth Technology Develops wound dressing care products	Director/Board Member	-

All active positions of Anki Malmborg Hager

Former positions of Anki Malmborg Hager

Companies	Position	End
NANOECHO AB	Director/Board Member	2026-05-27
Avena Partners AB	Director/Board Member	2024-09-25
Lund University Bioscience AB Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions.	Chief Investment Officer	-
ProNoxis AB ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation	Director/Board Member	-
░░ ░░░░░░ ░░	░░░░░░░░░	░░░░░░░░░░

See the detail of Anki Malmborg Hager's experience

Education of Anki Malmborg Hager

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Anki Malmborg Hager's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	18
Alligator Bioscience AB Alligator Bioscience AB BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops antibodies for the treatment of cancers	Health Technology
University of Lund University of Lund Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Lund University Bioscience AB Lund University Bioscience AB Investment ManagersFinance LU Bio's investment objective is to create value growth in their innovations for all stakeholders such as the inventors, Lund University, investors and society. Their investment strategy seeks to invest in start-up, early-stage or early-expansion phase projects in the life science field which require capital. They invest across the Nordic region of Sweden, Denmark, Finland and Norway, with a particular focus on Sweden. LU Bio is an active investment partner. They provide both capital and industrial development know-how with the goal of accelerating efficient development of life science innovations. They look to develop high-growth, high-technology and focused portfolio firms. The firm aims to grow defensible and dominant market positions.	Finance
Immunovia AB Immunovia AB Pharmaceuticals: MajorHealth Technology Provides blood-based test for diagnosis of pancreatic cancer	Health Technology
ProNoxis AB ProNoxis AB Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs to treat chronic inflammation	Health Technology
WC Likvid AB WC Likvid AB Real Estate DevelopmentFinance Owns and manages movable and immovable property	Finance
Cantargia AB Cantargia AB Pharmaceuticals: MajorHealth Technology Creates and develops antibody therapeutics for the treatment of leukemia	Health Technology
Sista versen 26366 AB Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Discovers treatments for inflammatory disorders	Health Technology
SenzaGen AB SenzaGen AB BiotechnologyHealth Technology Develops in vitro test methods for prediction of chemical and protein sensitizers	Health Technology
Diaprost AB Diaprost AB Miscellaneous Commercial ServicesCommercial Services Provides research services	Commercial Services
Hager Consulting AB
Avena Partners AB
Bulb Intelligence AB
Executive Foundation Lund Executive Foundation Lund Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Xlmmune AB Xlmmune AB Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparation	Health Technology
Nanoecho AB Nanoecho AB Medical SpecialtiesHealth Technology Develops medical ultrasound imaging equipment to treat rectal cancer	Health Technology
Colzyx AB Colzyx AB Medical SpecialtiesHealth Technology Develops wound dressing care products	Health Technology
PainDrainer AB PainDrainer AB Medical SpecialtiesHealth Technology Develops digital pain management tools	Health Technology